€5m · Other round · Healthtech · Paris, France
En Carta Diagnostics, a Paris-based developer of at-home molecular tests, has raised €5 million in a first closing. The financing comprises €3 million in equity led by Blue Forest Ventures and €2 million in non-dilutive funding from Bpifrance and other partners.
Ring Capital joined the equity portion alongside existing investors CentraleSupélec Venture, 50 Partners Health and business angels. En Carta will use the capital for regulatory certification in Europe and the US, industrialisation and commercial launch, beginning with an early Lyme disease test and followed by sexually transmitted infection screening.
En Carta is trying to bring laboratory testing into a home cassette
The company’s platform combines aptamers, which bind to specific molecular targets, with a cassette designed to return results in about 30 minutes. Its aim is to offer the accuracy of laboratory PCR in a format that patients or clinicians can use closer to the point of need.
That matters for Lyme disease because existing tests may not detect infection until weeks after a tick bite. En Carta has received FDA Breakthrough Device designation for its Lyme test and is running clinical trials in Boston and Bialystok, Poland. The designation can accelerate regulatory interaction, but it does not replace the evidence required for clearance.
Regulation, manufacturing and distribution must advance together
Diagnostics companies often face three linked risks: proving clinical performance, manufacturing reliably at scale and securing routes to market. En Carta is pursuing a fabless model with Circum Medical for hardware production, which can reduce capital intensity but makes supplier execution and quality systems central to the launch.
The company has also signed a €13 million co-development and commercialisation agreement with French self-test specialist AAZ for chlamydia and gonorrhoea tests, including committed volumes over five years. That partnership provides an early distribution signal, while the new financing funds the regulatory and industrial work needed to turn those commitments into approved products.
Sources checked:
company announcement · EIT Health Startups · Tech.eu Funding Explorer
